Circulating matrix metalloproteinases in infective endocarditis: a possible marker of the embolic risk. - Wikidata - awgldk - TriplyDB

Circulating matrix metalloproteinases in infective endocarditis: a possible marker of the embolic risk.

Circulating matrix metalloproteinases in infective endocarditis: a possible marker of the embolic risk.

http://www.wikidata.org/entity/Q33886654

about

Targeting matrix metalloproteinase activity and expression for the treatment of viral myocarditis.Prediction of Symptomatic Embolism in Filipinos With Infective Endocarditis Using the Embolic Risk French Calculator.

P2860

Q38174997-78935876-496A-4001-99FB-D5EEF24B72F3 Q38961468-7A1A6E97-AF2D-4FA0-A798-1B47DD462F89

P2860

Circulating matrix metalloproteinases in infective endocarditis: a possible marker of the embolic risk.

http://www.wikidata.org/entity/Q33886654

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

Circulating matrix metalloprot ...... le marker of the embolic risk.

@ast

Circulating matrix metalloprot ...... le marker of the embolic risk.

@en

type

label

Circulating matrix metalloprot ...... le marker of the embolic risk.

@ast

Circulating matrix metalloprot ...... le marker of the embolic risk.

@en

prefLabel

Circulating matrix metalloprot ...... le marker of the embolic risk.

@ast

Circulating matrix metalloprot ...... le marker of the embolic risk.

@en

P1433

Q33886654-64EBDFD1-A489-472A-AA55-AB8797471CF2

P1476

Q33886654-BEA3FAF9-1E47-451F-8F42-44E4A2A89E5E

P2093

Q33886654-09824220-2CAB-4AF7-9A56-2A23C10079B0

Q33886654-1246A2F6-0FE3-4CD3-AB76-26E572AC3A85

Q33886654-4D9C89EF-E114-458B-929B-2A1AC7C6B45E

Q33886654-57B5150C-69BC-438E-8C2C-23A49743B60A

Q33886654-88CBC85E-9039-43A6-91CC-F2DB8C1E0701

Q33886654-DBB0875E-1C6B-49E5-8C92-DD87BC30DE4A

Q33886654-E3E8CC99-EE23-4290-8B42-63554F538B61

Q33886654-F3E57A64-237B-44EC-9570-7301A04AC7FA

P2860

Q33886654-10D647B7-1892-4395-A6AB-EB59579E8EB1

Q33886654-172AEEB3-1D2D-41E5-AAE2-CA18A9D97831

Q33886654-198CA381-A813-4A18-9AAE-B99E1438DCEC

Q33886654-215421D8-30A7-484B-B9CF-C827C38E22AD

Q33886654-4377532D-4798-4EF1-8D10-3FB5BB31ABF1

Q33886654-5206589E-DD39-4AC1-9044-2DB6876FFA7D

Q33886654-528DE224-2B91-475F-9323-DCF54385B02D

Q33886654-53F47AAB-7FF7-4304-8F2A-E08F7D018B52

Q33886654-590780D2-605C-40A5-A9EB-766111852C73

Q33886654-603EBFCB-752D-402C-B8DD-6DE269B7EC97

P304

Q33886654-F7F61E05-40C1-4BF9-8D72-E76AB57A8A15

P31

Q33886654-EBE23504-0E06-4266-825A-ADAF86197869

P356

Q33886654-BAEE67DA-ACAE-469D-801C-E62C990DCBA1

P407

Q33886654-7087D513-82EF-4317-8FE6-2A78289499AD

P433

Q33886654-85E218FD-E328-4194-8D79-E7CABF8A0883

P478

Q33886654-6988F8D7-81DC-44AA-ABC2-5CCB9142BA2E

P50

Q33886654-50959C71-5061-4AA0-A308-8083EA52A351

Q33886654-830DED12-ABE3-43CC-ABED-1585E99F249D

Q33886654-C83B02A4-F497-46F8-BA4E-F2BBE69D76A0

P577

Q33886654-1B4FE5A4-F830-4AE3-91FE-ABCDF935BDFE

P5875

Q33886654-78D47C61-F590-4259-9C94-D4EE39632269

P698

Q33886654-08F53A88-25C0-4F16-8BA8-7A0A4E0A57B1

P932

Q33886654-817D5871-8F21-4198-9490-96F427F1FC4D

P356

JOURNAL.PONE.0018830

P1433

P1476

Circulating matrix metalloprot ...... le marker of the embolic risk.

@en

P2093

Franck Thuny

http://www.w3.org/2001/XMLSchema#string

Jean-François Avierinos

http://www.w3.org/2001/XMLSchema#string

Jean-Louis Mege

http://www.w3.org/2001/XMLSchema#string

Jean-Paul Casalta

http://www.w3.org/2001/XMLSchema#string

Marie-Christine Alessi

http://www.w3.org/2001/XMLSchema#string

Monique Verdier

http://www.w3.org/2001/XMLSchema#string

Pierre-Emmanuel Morange

http://www.w3.org/2001/XMLSchema#string

Yvan Le Dolley

http://www.w3.org/2001/XMLSchema#string

P2860

2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Commit

Matrix metalloproteinases: effectors of development and normal physiology

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Improvement in the diagnosis of abscesses associated with endocarditis by transesophageal echocardiography.

The transcriptional programme of human heart valves reveals the natural history of infective endocarditis.

Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis.

Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Y

Matrix metalloproteinases: regulation and dysregulation in the failing heart.

Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the Eu

Increased expression and activity of matrix metalloproteinases characterize embolic cardiac myxomas.

P304

e18830

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0018830

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Matthias Canault

P577

2011-04-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51089391

http://www.w3.org/2001/XMLSchema#string

P698

21533198

http://www.w3.org/2001/XMLSchema#string

P932

3077407

http://www.w3.org/2001/XMLSchema#string